Investor Presentation: August 2022
CYTR
OTCQB: CYTR
CORPORATE OVERVIEW August 2022
CytRx Safe Harbor Statement
THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS "INTENDS," "MAY," "WILL," "PLANS," "EXPECTS," "ANTICIPATES," "PROJECTS," "PREDICTS," ESTIMATES," "AIMS," "BELIEVES," "HOPES," "POTENTIAL" OR SIMILAR WORDS. FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF MANAGEMENT AS WELL AS
CERTAIN ASSUMPTIONS MADE BY AND INFORMATION CURRENTLY AVAIALABLE TO MANAGEMENT, ARE NOT GUARANTEES OF FUTURE PERFORMANCE, AND ARE SUBJECT TO VARIOUS KNOWN AND UNKNOWN RISKS AND
UNCERTAINTIES, MANY OF WHICH ARE BEYOND CYTRX'S CONTROL, AND CANNOT BE PREDICTED OR QUANTIFIED AND
CONSEQUENTLY, RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD- LOOKING STATEMENTS AS A RESULT OF VARIOUS RISKS AND UNCERTAINTIES, INCLUDING THOSE RISK FACTORS DISCUSSED IN THE ANNUAL AND QUARTERLY REPORTS THAT CYTRX FILES WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION. STATEMENTS CONTAINED HEREIN ARE MADE AS OF THE DATE OF THIS PRESENTATION UNLESS STATED OTHERWISE, AND NEITHER THIS PRESENTATION, NOR ANY SALE OF SECURITIES, SHALL UNDER ANY CIRCUMSTANCES CREATE AN IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME AFTER SUCH DATE OR THAT INFORMATION WILL BE UPDATED OR REVISED TO REFLECT INFORMATION THAT SUBSEQUENTLY BECOMES AVAILABLE OR CHANGES OCCURRING AFTER THE DATE HEREOF. CYTRX RESERVES THE RIGHT TO UPDATE, AMEND OR SUPPLEMENT THE INFORMATION AT ANY TIME IN ITS ABSOLUTE DISCRETION (WITHOUT INCURRING ANY OBLIGATION TO DO SO). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE DOCUMENTS FREE OF CHARGE ON THE SEC'S WEB SITE AT WWW.SEC.GOV. CYTRX ASSUMES NO OBLIGATION TO PUBLICLY UPDATE OR REVISE ITS FORWARD-LOOKING STATEMENTS AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.
2
Management and Board
Stephen Snowdy, PhD
Gilad Gordon, MD
John Caloz
CEO
R&D/Regulatory
CFO
•
Recently joined CytRx
Consultant
•
30+ years of CFO
•
PhD Neurobiology
•
Oncology development
experience in life
University of North
expert
sciences sector
Carolina
•
30 years experience
•
Occulogix, IRIS Int'l,
•
20 years of experience
developing cancer
Synarc, Phoenix Int'l
in medical executive
treatments
Life Sciences
management
•
Directly responsible
for
•
Venture capital
50 INDs, hundreds
of
•
Medical devices
clinical trials
Board of Directors
Chair of the Board. CEO of Panbela
Therapeutics. Former CEO of Delcath,
Oncology Lead at Imclone, Product
Director Oncology Marketing at Ortho
Biotech
Chair of Audit Committee. 30 years of experience in tax, finance, and auditing.
Chair of the Compensation Committee.
CEO of Adial Pharmaceuticals Inc.
Former CEO of Prosperity Capital
Management, LLC.
3
Investment Highlights
CytRx has developed elegant tumor targeting and
release molecules called LADR that are based on
CytRx is stage-diversified, with LADR-based drugs stretching
small molecular entities (no complex antibodies or
from registrational Phase 2 in pancreatic cancer to late pre-
nanoparticles) allowing for higher dosing and
clinical next-gen drugs
lower off-target tox
4
LADR=Linker Activated Drug Release
LADR-based drugs take advantage of circulating albumin as Trojan Horse:
LADR:
Ultra High Potency Drug
Payload
Cleavable Linker
Targeting
* Kratz, F. Albumin as a drug carrier. J Cont Rel (2008) 132:171-183
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Disclaimer
CytRx Corporation published this content on 10 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2022 23:09:03 UTC.